Please assess the completion status of the following clinical trial:

Trial Title: A Study Using Electronic Health Information to Learn About Rivaroxaban Compared to Warfarin in Participants With Non-valvular Atrial Fibrillation (NVAF) and Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Be ≥18 years of age at the time of anticoagulation initiation~* Have diagnoses of type 2 diabetes and Non-valvular atrial fibrillation (NVAF)~* Have no record of prior oral anticoagulant (OAC) use in the prior 12-months~* Newly initiated on Rivaroxaban or Warfarin (index date)~* Have ≥12-months of electronic health record (EHR) activity prior to the index date and received care documented in the EHR database from at least one provider in the 12-months prior~Exclusion Criteria:~* Evidence of valvular heart disease defined as any rheumatic heart disease, mitral stenosis or mitral valve repair/replacement~* Pregnancy~* Use of rivaroxaban doses other than 15 mg once daily or 20 mg once daily or the presence of other indication(s) for OAC use~* Any prior OAC utilization per written prescription or self-report at baseline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: None): Participants with diagnoses of type 2 diabetes and non-valvular atrial fibrillation (NVAF) newly-initiated on rivaroxaban
- Group B (Type: None): Participants with diagnoses of type 2 diabetes and non-valvular atrial fibrillation (NVAF) newly-initiated on warfarin

Based on this trial design, predict the completion outcome and termination type (if applicable).